MoonLake Immunotherapeutics (MLTX) Return on Invested Capital (2022 - 2026)

MoonLake Immunotherapeutics' Return on Invested Capital history runs 5 years deep, the most recent figure standing at 0.01% for Q1 2026.

• In Q1 2026, Return on Invested Capital changed 0.0% year-over-year to 0.01%; the TTM figure through Mar 2026 stood at 0.01% (changed 0.0% YoY), while the FY2025 annual figure was 0.01%, changed 0.0% from the prior year.
• Return on Invested Capital was 0.01% for Q1 2026 at MoonLake Immunotherapeutics, down from 0.01% in the prior quarter.
• In the past five years, Return on Invested Capital ranged from a high of 0.1% in Q1 2022 to a low of 0.03% in Q2 2022.
• Historically, Return on Invested Capital has averaged 0.0% across 5 years, with a median of 0.0% in 2025.
• Biggest YoY gain for Return on Invested Capital was 2 bps in 2023; the steepest drop was 11 bps in 2023.
• A 5-year view of Return on Invested Capital shows it stood at 0.01% in 2022, then surged by 87 bps to 0.0% in 2023, then plunged by 181 bps to 0.0% in 2024, then plunged by 118 bps to 0.01% in 2025, then fell by 11 bps to 0.01% in 2026.
• The last three Return on Invested Capital figures came in at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.